+249 % change
Extra-EU imports of CN 30025100 were up 249% in 2025 compared with 2022 (€190.1 million), calculated from Eurostat values.
Eurostat314.0 EUR million
EU exports of CN 30025100 to countries outside the EU were worth €314.0 million in 2025.
Eurostat450.6 EUR million
Trade between EU member states in CN 30025100 (intra-EU arrivals) came to €450.6 million in 2025.
EurostatSource: Eurostat
Why this market is moving now
- Extra-EU import value moved +249% from 2022 to 2025, a direct read on EU demand for sourced supply.
- Supply is concentrated: one country provided a large share of extra-EU imports in 2025.
- US employment in the core industry shifted +8% since 2020.
- Clinical research is active, with studies recruiting now.
What this market covers
Production of cell therapy products, including collection, modification, expansion and release testing. Handled by developers and contract manufacturers.
Typical segments
- Autologous manufacturing
- Allogeneic manufacturing
- Viral vector supply
- Process equipment
Who buys
- Cell therapy developers
- Biopharma companies
- Hospitals
Largest non-EU suppliers to the EU
| Country | Import value |
|---|---|
| United States from 1995 -> 2000) | 490.6 EUR million |
| Switzerland | 149.7 EUR million |
| United Kingdom | 21.3 EUR million |
| China | 1.0 EUR million |
| Brazil | 0.1 EUR million |
| Korea, Republic of | 0.1 EUR million |
Key figures
Each figure links to the page it came from.
| Figure | Value | Year | Source |
|---|---|---|---|
| The EU imported €662.9 million of products under CN code 30025100 (Cell therapy products) from outside the EU in 2025. | 662.9 EUR million | 2025 | Eurostat |
| Extra-EU imports of CN 30025100 were up 249% in 2025 compared with 2022 (€190.1 million), calculated from Eurostat values. | +249 % change | 2025 | Eurostat |
| EU exports of CN 30025100 to countries outside the EU were worth €314.0 million in 2025. | 314.0 EUR million | 2025 | Eurostat |
| Trade between EU member states in CN 30025100 (intra-EU arrivals) came to €450.6 million in 2025. | 450.6 EUR million | 2025 | Eurostat |
| United States from 1995 -> 2000) was the largest non-EU supplier of CN 30025100 to the EU in 2025, with €490.6 million, or 74% of extra-EU imports. | 490.6 EUR million | 2025 | Eurostat |
| EU exports of CN 30025100 to the United States were €43.4 million in 2025. | 43.4 EUR million | 2025 | Eurostat |
| The average value of extra-EU imports of CN 30025100 was €10,949.99 per kilogram in 2025, calculated from Eurostat value and weight. | 10,949.99 EUR per kg | 2025 | Eurostat |
| Netherlands was the largest EU exporter of CN 30025100 to non-EU countries in 2025, at €237.3 million. | 237.3 EUR million | 2025 | Eurostat |
| The EU had 3,116 enterprises in NACE class C2120 (Manufacture of pharmaceutical preparations) in 2023. | 3,116 enterprises | 2023 | Eurostat |
| EU enterprises in NACE class C2120 had net turnover of €428.65 billion in 2023. | 428.65 EUR billion | 2023 | Eurostat |
| NACE class C2120 employed 600,730 people across the EU in 2023. | 600,730 persons employed | 2023 | Eurostat |
| The US had 5,013 private establishments in NAICS 325412 (Pharmaceutical preparation manufacturing) in 2025. | 5,013 establishments | 2025 | U.S. Bureau of Labor Statistics |
| NAICS 325412 employed an average of 229,922 people in US private industry in 2025. | 229,922 jobs | 2025 | U.S. Bureau of Labor Statistics |
| US employment in NAICS 325412 changed by +8% between 2020 (212,670 jobs) and 2025, calculated from BLS figures. | +8 % change | 2025 | U.S. Bureau of Labor Statistics |
| Average annual pay in US NAICS 325412 was $158,377 in 2025. | 158,377 USD per year | 2025 | U.S. Bureau of Labor Statistics |
| ClinicalTrials.gov lists 20,294 registered studies for the condition "cell therapy". | 20,294 registered studies | 2026 | U.S. National Library of Medicine (ClinicalTrials.gov) |
| 3,387 of those studies were recruiting participants when checked in November 2026. | 3,387 recruiting studies | 2026 | U.S. National Library of Medicine (ClinicalTrials.gov) |
What the full report covers
- 1
Executive summary
The answer on two pages: size, growth and what drives it.
- 2
Market size and outlook
History, the current year and a five-year view with base, low and high cases.
- 3
Segments and regions
Splits by product, buyer and geography across the US, Europe and MEA.
- 4
Company profiles
The main players, how they compete and where they are investing.
- 5
Data and method
Every figure in Excel, with the sources and assumptions behind it.
- 01Executive summary
The answer in one page: size, direction and what moves it - 02Market definition and scope
What is in and out of the European Union market - 03Market size, 2021 to 2025
Historical series and growth rates - 04Outlook to 2031
Base, low and high scenarios with stated assumptions - 05Rules, policy and deadlines
Regulation and programmes that change demand - 06Drivers and barriers
What accelerates or slows adoption, by customer segment - 07Prices, costs and margins
Unit economics where public data allows - 08Competitive landscape
8 to 12 company profiles with recent moves - 09Opportunities and risks
For new entrants, suppliers and investors - 10Method and sources
Every assumption and source, listed
Included with the full report
- PDF report, 40 to 60 pages
- Excel data pack
- Ready-to-use charts
- Method note and assumptions
- Written to order in 5 working days
Frequently asked questions
How big is the EU cell therapy manufacturing market?
There is no single official market total. Eurostat trade data shows the EU imported €662.9 million of goods under CN 30025100 from outside the EU in 2025 and exported €314.0 million.
Where does the EU import cell therapy manufacturing from?
United States from 1995 -> 2000) was the largest non-EU supplier in 2025. The next largest were Switzerland, United Kingdom, China.
What is the average import price of cell therapy manufacturing in the EU?
Dividing Eurostat import value by weight gives about €10,949.99 per kilogram for CN 30025100 in 2025.
Which EU countries export the most cell therapy manufacturing?
Netherlands led EU exports to non-EU countries in 2025, followed by Italy, Germany.
How many clinical trials study cell therapy?
ClinicalTrials.gov lists 20,294 registered studies.
How many US companies are in the cell therapy manufacturing industry?
BLS counts 5,013 private establishments in NAICS 325412 (Pharmaceutical preparation manufacturing), the closest official industry.
Sources and method
The figures on this page come from the public sources listed below. Read how we work.
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter EU27_2020, product 30025100, partner EXT_EU27_2020, flow import, 2025, VALUE_IN_EUROS 662868676
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter EU27_2020, product 30025100, flow import, 2022 VALUE_IN_EUROS 190083772; 2025 VALUE_IN_EUROS 662868676
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter EU27_2020, product 30025100, partner EXT_EU27_2020, flow export, 2025, VALUE_IN_EUROS 313986148
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter EU27_2020, product 30025100, partner INT_EU27_2020, flow import, 2025, VALUE_IN_EUROS 450600631
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter EU27_2020, product 30025100, partner US, flow import, 2025, VALUE_IN_EUROS 490623860
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter EU27_2020, product 30025100, partner US, flow export, 2025, VALUE_IN_EUROS 43422924
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter EU27_2020, product 30025100, flow import, 2025, VALUE_IN_EUROS 662868676, QUANTITY_IN_100KG 605
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter NL, product 30025100, partner EXT_EU27_2020, flow export, 2025, VALUE_IN_EUROS 237289362
- Eurostat: Enterprises by detailed NACE Rev. 2 activity and special aggregates (sbs_ovw_act) (2026-11-04)
sbs_ovw_act, geo EU27_2020, nace_r2 C2120, indic_sbs ENT_NR, 2023, 3116
- Eurostat: Enterprises by detailed NACE Rev. 2 activity and special aggregates (sbs_ovw_act) (2026-11-04)
sbs_ovw_act, geo EU27_2020, nace_r2 C2120, indic_sbs NETTUR_MEUR, 2023, 428651
- Eurostat: Enterprises by detailed NACE Rev. 2 activity and special aggregates (sbs_ovw_act) (2026-11-04)
sbs_ovw_act, geo EU27_2020, nace_r2 C2120, indic_sbs EMP_NR, 2023, 600730
- U.S. Bureau of Labor Statistics: QCEW annual averages, NAICS 325412, 2025 (2026-11-04)
QCEW 2025 annual, US000, private, NAICS 325412, annual_avg_estabs 5013
- U.S. Bureau of Labor Statistics: QCEW annual averages, NAICS 325412, 2025 (2026-11-04)
QCEW 2025 annual, US000, private, NAICS 325412, annual_avg_emplvl 229922
- U.S. Bureau of Labor Statistics: QCEW annual averages, NAICS 325412, 2025 (2026-11-04)
QCEW 2020 annual_avg_emplvl 212670; 2025 annual_avg_emplvl 229922
- U.S. Bureau of Labor Statistics: QCEW annual averages, NAICS 325412, 2025 (2026-11-04)
QCEW 2025 annual, US000, private, NAICS 325412, avg_annual_pay 158377
- U.S. National Library of Medicine (ClinicalTrials.gov): ClinicalTrials.gov API v2, condition "cell therapy" (2026-11-04)
query.cond=cell therapy totalCount 20294
- U.S. National Library of Medicine (ClinicalTrials.gov): ClinicalTrials.gov API v2, condition "cell therapy", status recruiting (2026-11-04)
filter.overallStatus=RECRUITING totalCount 3387
Free sample
Get a free sample of this report
We send the table of contents, two sample chapters and the method note, usually within one working day. You owe us nothing for asking.
- Full table of contents
- Two sample chapters
- Method note and data outline